You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(00460.HK)近期股價異動 將持續致力保持和Hugel長期戰略合作關係
格隆匯 09-30 07:21

格隆匯9月30日丨四環醫藥(00460.HK)發佈公吿,董事會注意到最近幾日公司股票價格和交易量的異常變化。經過對公司在該種情況下所做出的一切合理查詢後,董事會確認,除該公吿所披露內容外,董事會並不知悉任何導致股票價格和交易量變動的原因,或任何必須公佈以避免公司證券出現虛假市場的資料,或任何根據證券及期貨條例(香港法例第571章)第XIVA部項下須予披露的內幕消息。

公司注意到近期有媒體就康橋資本對Hugel,Inc的收購做出報導,其中有報導稱集團未來對Hugel某些產品在中國的獨家代理權將會受到Hugel收購的影響。根據公司於2021年8月27日發佈的公吿中所披露,公司相信集團與Hugel就A型肉毒毒素(樂提葆®)及玻尿酸產品訂立的獨家分銷協議的條款及其項下的權利不會因Hugel收購而受到影響。

公司進一步注意到界面新聞於2021年9月27日發佈的關於康橋資本獨家迴應的相關報導。集團旗下醫美業務主體北京渼顏空間科技有限公司於2021年9月10日以侵犯商業祕密為由起訴康橋資本,該訴訟已被北京知識產權法院正式受理。公司希望強調,集團將根據所有適用法律來積極尋求保護其權利。集團自與Hugel簽署獨家分銷協議以來,一直是Hugel在中國的長期戰略合作伙伴,集團將持續致力於保持和Hugel的長期戰略合作關係。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account